Compared with eplerenone, considered the safer alternative to spironolactone, Finerenone was similarly effective in reducing NT-proBNP but demonstrated a safer clinical profile, placing it at the forefront of MRAs for safety, as demonstrated in the AA randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease (ARTS-HF) trial [27]. Here, NPPB is linked to congestive heart failure.